|
|
|
|
|
|
| Abstract Search | Browse Program and Abstracts | Schedule-at-a-Glance | Conference Mission & Sponsors | Program Committee | Contact Us |
| # | Title |
|---|---|
| 152 | Immune Serum Transfers Protection Mediated by HIV-1 rgp120 against SHIV Challenge
N. Almond1, A. Wade-Evans1, E. J. Stott1, B. Walker1, R. Hull1, G. Voss2, S. Cayphas*2, and R. Stebbings1 1NIBSC, UK and 2GlaxoSmithKline, Rixensart, Belgium |
| 153 | Transient HIV-1 Infection in Sooty Mangabey and Pig-Tailed Macaque Cells: Lack of Viral Integration?
S. Owen*1, S. Masciotra1, H. McClure2, F. Novembre2, and R. Lal1 1 CDC, Atlanta, GA, USA and 2Yerkes Primate Ctr., Emory Univ., Atlanta, GA, USA |
| 154 | Inclusion of Vpr Accessory Gene Plasmid with Vaccines Encoding Multiple HIV-1 Antigens Markedly Reduces Vaccine Effectiveness and Antigen-Specific Effector T-Cell Function in Vivo Resulting in CD4 Cell Loss and Increased Viral Loads in Rhesus Macaques
K. Muthumani1, V. Ayyavoo4, D. Conway3, S. Kudchodkar1, D. Zhang1, J. Kim6, J. Boyer1, L. Montaner2, K. Manson5, M. Bagarazzi3, and D. Weiner*1 1Univ. of Pennsylvania, Philadelphia, USA; 2The Wistar Inst., Philadelphia, PA, USA; 3St. Christopher’s Hosp. for Children, Philadelphia, PA, USA; 4Univ. of Pittsburgh, Pittsburgh, PA, USA; 5Primedica, Inc. Worcester, MA, USA; and 6Viral Genomix, Philadelphia, PA, USA |
| 155 | Plasmid Vaccines Encoding SIV gag/pol and env/rev Control Viral Load and Protect CD4 T Cells from Mucosal SIV251 Challenge of Rhesus Macaques
M. Bagarazzi*2, K. Muthumani1, D. Conway2, S. Kudchodkar1, J. Kim3, J. Boyer1, and D. Weiner1 1Univ. of Pennsylvania, Philadelphia, USA; 2MCP Hahnemann Univ., Philadelphia, PA, USA; and 3Viral Genomix, Philadelphia, PA, USA |
| 156 | High Levels of Nonfunctional Proviral DNA in DNA/MVA Vaccinated Animals with Controlled Viral Infections
Y. Tang*, R. R. Amara, F. Villinger, S. Staprans, N. Kozyr, B. Grimm, J. Smith, S. Lydy, and H. L. Robinson Emory Univ., Atlanta, GA, USA |
| 157 | Implications of Variation in SHIV/SIV Challenge Strains Used in Preclinical HIV Vaccine Trials
M. Feinberg1, J. Cohen2, A. Barry1, N. Kozyr1, D. Garber1, G. Silvestri1, H. McClure1, H. Robinson1, and S. Staprans*1 1Emory Univ., Atlanta, GA, USA and 2NIH, Bethesda, MD, USA |
| 158 | HIV Envelope Peptide Cocktail Vaccine Protects against Chronic Infection and AIDS in the SHIV-Rhesus Model
P. N. Nehete*1, S. Chitta1, M. M. Hossain1, L. Hill1, R. B. Arlinghaus2, and K. J. Sastry1 Univ. of Texas M. D. Anderson Cancer Ctr., 1Bastrop, USA and 2Houston, USA |
| 159 | Protection by SIV VLP DNA Prime/Protein Boost following Mucosal SIV Challenge Is Markedly Enhanced by IL-12/GM-CSF Coadministration
E. O’Neill*1, I. Martinez1, Z. Israel2, F. Villinger3, M. Sidhu2, R. Stout5, D. Montefiori4, A. A. Ansari3, M. Martinez1, and E. Kraiselburd1 1Caribbean Primate Res. Ctr. and Univ. of Puerto Rico-MSC, San Juan, Puerto Rico; 2Wyeth-Lederle Vaccines, Pearl River, NY, USA; 3Emory Univ., Atlanta, GA, USA; 4Duke Univ., Durham, NC, USA; and 5Bioject Inc., Portland, OR, US |
| 160 | Molecular Construction and in Vivo Transmission of a Simian-Human Immunodeficiency Virus (SHIV) Encoding Envelope Gene of CCR5 Tropic HIV-1 Ba-L
R. Pal*1, J. S. Foulke2, M. Merges2, A. Gibson1, R. Woodward1, P. Markham1, and M. Reitz2 1Advanced BioSci. Labs, Kensington, MD, USA and 2Inst. of Human Virology, Baltimore, MD, USA |
| 161 | Anti-Nef SIV DNA Vaccination of Macaques Induces Multi-Specific Anti-Nef T-Cell Responses and Protection against Challenge with SIVmac251
E. Bonnin, P. Lefèbvre, I. Couillin, F. Letourneur, J.-G. Guillet, and F. Martinon* ICGM-INSERM, Paris, France |
| 162 | Low Dose of IL-2 as an Adjuvant to an NYVAC-SIV-gag-pol-env-Based Vaccine Expands Preferentially Virus-Specific Dominant Epitopes and Decreases Proliferative Response to SIV p27 Gag and Env in SIVmac251-Infected Macaques
E. Tryniszewska1, J. Nacsa1, Z. Hel1, W.-P. Tsai1, L. Stevceva1, R. W. Parks1, M. Moniuszko1, M. Lewis2, K. Smith3, J. Tartaglia4, and G. Franchini*1 1NCI, Bethesda, MD, USA; 2SRI, Frederick, MD, USA; 3Cornell Univ., New York, NY, USA; and 4Aventis-Pasteur, Toronto, Canada |
| 163 | Transfusion Of Pre SIV Infection Collected Autologous CD4+ Cells Is Sufficient To Induce A Longterm Non Progressor Status In Chronically Infected Rhesus Monkeys.
F. Villinger1*, G. T. Brice2, A. E. Mayne1, P. Bostik1, K. Mori3, C. H. June4, and A. A. Ansari1 1Dept of Pathology, Emory University of Medicine, Atlanta GA, 2Naval Medical Research Institute, Silver Springs MD, 3AIDS Research Center, Tsukuba Primate Center, Tsukuba Japan, 4Cancer Research Institute, University of Pennsylvania, Philadelphia PA. |
| 164 | Prime vs. Prime-Boost Vaccinations with a Recombinant MVA Virus Expressing SHIV-89.6 env, gag, and pol Followed by Soluble gp140 Protein
P. Earl*1, L. Wyatt1, D. Montefiori2, M. Bilska2, R. Woodward3, P. Markham3, J. Malley1, T. Vogel4, T. Allen4, D. Watkins4,5, N. Miller1, and B. Moss1 1NIH, Bethesda, MD, USA; 2Duke Univ. Med. Ctr., Durham, NC, USA; 3Advanced BioSci. Labs, Inc., Kensington, MD, USA; 4Wisconsin Regional Primate Res. Ctr., Madison, USA; and 5Univ. of Wisconsin, Madison, USA |
| 165 | Better Control of a Pathogenic SHIV89.6p Challenge by Gag-Pol-Env than Gag-Pol DNA/MVA Vaccine: Requirement for Inclusion of Envelope in AIDS Vaccines
R. Amara*, J. Smith, F. Villinger, J. Altman, S. Staprans, N. Kozyr, S. Lydy, and H. Robinson Emory Univ., Atlanta, GA, USA |
| 166 | Lack of Immunopathologic Responses as a Possible Protective Mechanism against Disease Development in the Natural Primate Hosts of SIV
S. Norley*1, S. Holzammer2, B. Beer3, E. Holznagel2, C. Brown3, and R. Kurth1 1Robert Koch-Inst., Berlin, Germany; 2Paul-Ehrlich-Inst., Langen, Germany; and 3 NIAID, NIH, Rockville, MD, USA |
| 167 | Use of the Nonpathogenic Rev-Independent SIV to Dissect Correlates of Protective Immunity
A. von Gegerfelt1, V. Liska2, M. Marthas3, P. Markham4, N. Miller5, R. Ruprecht2, and B. K. Felber*1 1NCI at Frederick, MD, USA; 2Dana-Farber Cancer Inst., Boston, MA, USA; 3California Regional Primate Res. Ctr., Davis, USA; 4Advanced BioScience Labs, Inc., Kensington, MD, USA; and 5NIAID, NIH, Bethesda, MD, USA |
| 168 | Prevention of Disease Induced by Heterologous SHIV Challenge in Rhesus Monkeys Using a Multicomponent Subunit AIDS Vaccine
P. Vandepapeliere*1, K. Manson2, P. Mooij3, D. Montefiori4, D. Watkins5, J. Heeney3, M. Wyand2, J. Cohen1, C. Bruck1, and G. Voss1 1GlaxoSmithKline Biologicals, Rixensart, Belgium; 2Primedica, Worcester, MA, USA; 3Biomedical Primate Res. Ctr., Rijswijk, The Netherlands; 4Duke Univ. Med. Ctr., Durham, NC, USA; and 5Wisconsin Regional Primate Res. Ctr., Madison, USA |
| 169 | An Infectious Simian/Human Immunodeficiency Virus with Human Immunodeficiency Virus Type 1 Subtype C from an African Isolate: Rhesus Macaque Model
T. Ndung'u*, Y. Lu, B. Renjifo, N. Touzjian, N. Kushner, V. Pena-Cruz, V. A. Novitsky, T. H. Lee, and M. Essex Harvard Univ., Boston, MA, USA |
| 170 | Evaluation of the Immunogenicity of HIV-1 Vaccines in Baboons
A. Tang*1, D. R. Casimiro1, M. Davies1, T. Fu1, L. Chen1, K. Wilson1, K. Murthy2, K. Rice2, D. Freed1, D. Kaslow1, E. Emini1, and J. W. Shiver1 1Merck Res. Labs, West Point, PA, USA and 2Southwest Fndn. for Biomedical Res., San Antonio, TX, USA |
| 171 | Maturation of SIV Envelope "Domain-Specific" Antibody Responses Associated with the Development of Broadly Protective Immunity in Monkeys Inoculated with Attenuated SIV/17E
J. Rowles*, K. Stefano-Cole, M. Murphey-Corb, and R.C. Montelaro Univ. of Pittsburgh Sch. of Med., PA, USA |